Intra-arterial thrombolysis for acute ischemic stroke

European Radiology

Volumn 11, Issue 4, 2001, Pages 626-634

  Burnette, W C ^a   Nesbit, G M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cerebrovascular accident; Drug therapy; Fibrinolytic agents; Intra arterial infusions; Thrombolytic therapy

Indexed keywords

ABCIXIMAB; ALTEPLASE; HEPARIN; RETEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ALGORITHM; ARTICLE; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; THROMBOEMBOLISM;

ACUTE DISEASE; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR ACCIDENT; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0034879798     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003300000610     Document Type: Article

References (35)

1. Prognosis of acute stroke
2. Intra-arterial prourokinase for acute ischemic stroke. The PRO-ACT II study: A randomized controlled trial
3. Clinical course of acute middle cerebral artery occlusion
4. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease
5. Ischemic damage of brain microvessels: Inherent risks for thrombolytic treatment in stroke
6. Trials of streptokinase in severe acute ischemic stroke
7. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
8. Thrombolytic therapy with streptokinase in acute ischemic stroke
9. Tissue plasminogen activator for acute ischemic stroke
10. t-PA in acute ischemic stroke: Unites States experience and issues for the future
11. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3-5 h after symptom onset. The ATLANTIS study: A randomized controlled trial
12. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The standard treatment with Alteplase to reverse stroke (STARS) Study
13. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator
14. PROACT: A phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke
15. Local intra-arterial fibrinolysis in acute ischemic stroke
16. Local thrombolytic therapy for cerebrovascular disease: Current Oregon Health Sciences University experience (July 1991 through April 1995)
17. Intra-arterial thrombolysis in acute basilar artery thromboembolism: The initial Mayo Clinic experience
18. Fibrinolytic therapy for acute embolic stroke: Intravenous, intracarotid, and intra-arterial local approaches
19. Intra-arterial thrombolysis in acute ischemic stroke: Experience with a superselective catheter embedded in the clot
20. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation
21. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy
22. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator
23. Complications of cerebral angiography: Prospective assessment of risk
24. Complications of catheter cerebral arteriography: Analysis of 5000 procedures. I. Criteria and incidence
25. Results of urgent fibrinolysis in patients with major stroke and atherothrombotic occlusion of the cervical internal carotid artery
26. Clinical experience with diffusion-weighted MR in patients with acute stroke
27. Strategic considerations concerning emergency stroke treatment
28. Thrombolytic therapy in acute stroke
29. Local intra-arterial fibrinolysis in the carotid territory
30. Local intra-arterial fibrinolytic therapy in patients with stroke: Urokinase versus recombinant tissue plasminogen activator (r-TPA)
31. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study
32. Major mechanistic differences explain the higher clot lysis potency of Reteplase over Alteplase: Lack of fibrin bindings and advantage for bolus application of fibrin-specific thrombolytics
33. More rapid, complete, and stable coronary thrombolysis with bolus administration of Reteplase compared with Alteplase infusion in acute myocardial infarction
34. Direct percutaneous tansluminal angioplasty for acute middle cerebral artery occlusion